Metastatic Non-Small-Cell Lung Cancer
Source: Clinical Resources From inPractice Oncology

Table of Contents

 

Module

Leora Horn, MD, MSc, FRCPC, provides a comprehensive look at current optimal therapy for patients with metastatic NSCLC.

Learning Objectives

Upon completion of this activity, participants should be able to:

Topics Include:

  • Clinical Presentation and Evaluation
  • Molecular Testing for Advanced NSCLC
  • Treatment Options for Patients With Advanced NSCLC
  • Treatment Options for Patients With EGFR Mutations
  • Treatment Options for Patients With ALK Rearrangements
  • Treatment Options for Patients With ROS1 Rearrangements
  • Treatment Options for Patients With Adenocarcinoma and No Actionable Mutations
  • Treatment Options for Patients With Squamous Cell Carcinoma
  • Special Populations and Considerations for Treatment Selection
  • The Role of Early Palliative Care
  • Future Directions in Targeted Treatment for Metastatic NSCLC
  • Novel Targetable Pathways
     

    Faculty

    • Leora Horn
      MD, MSc, FRCPC
    • Release Date:
      December 02, 2016

    Information on this Educational Activity

    Faculty

    Leora Horn, MD, MSc, FRCPC


    Associate Professor of Medicine
    Clinical Director,
    Thoracic Oncology Research Program
    Assistant Vice Chairman for Faculty Development
    Vanderbilt Ingram Cancer Center
    Nashville, Tennessee

    Leora Horn, MD, MSc, FRCPC, has disclosed that she has consulted for AbbVie, Bristol-Myers Squibb, Genentech, Merck, Lilly, and Xcovery.
     

    Staff

    Kristen M. Rosenthal, PhD


    Managing Editor

    Kristen Rosenthal, PhD, has no real or apparent conflicts of interest to report.
     

    Gordon Kelley, 


    Senior Clinical Editor

    Gordon Kelley has no real or apparent conflicts of interest to report.
     

    Kevin Obholz, PhD


    Editorial Director, Hematology/Oncology

    Kevin Obholz, PhD, has no real or apparent conflicts of interest to report.